London, UK, 25 April 2023: PD Neurotechnology®, a medical device company, today announced that it has secured a strategic investment from Crimson International Investment (CII), the Al Jazira Group's investment arm that specializes in fast paced and disruptive technologies. In addition to the investment, CII, which is based in Abu Dhabi, will become the exclusive distributor of PDMonitor® in the Gulf countries.

PD Neurotechnology® has developed PDMonitor®, a medical-grade wearable device that automatically tracks the full range of Parkinson's motor symptoms on an ongoing basis, coupled with information on drug and food intake. It enables physicians to tailor treatment plans based on objective data showing the patients’ status in their day-to-day lives.

In January 2023, PDMonitor® was one of just five devices to be conditionally recommended for remote monitoring of Parkinson's disease to inform treatment by NICE, the National Institute for Health and Care Excellence. This decision opened the door to the use of PDMonitor® by NHS patients and their physicians in the UK.

Read more here